Literature DB >> 36063261

Clinically Complex LRBA Deficiency Due to a Founder Allele in the Georgian Jewish Population.

Tal Freund1, Sarah K Baxter2,3, Tom Walsh3, Hana Golan4,5, Joseph Kapelushnik6, Michal Abramsohn-Goldenberg7, Shira Benor1, Nadav Sarid8, Ron Ram8, Yifat Alcalay1, Reeval Segel9, Paul Renbaum9, Polina Stepensky10, Mary-Claire King3, Troy R Torgerson2,11, David Hagin12.   

Abstract

Pathogenic variants in LRBA, encoding the LPS Responsive Beige-Like Anchor (LRBA) protein, are responsible for recessive, early-onset hypogammaglobulinemia, severe multi-organ autoimmunity, and lymphoproliferation, with increased risk for malignancy. LRBA deficiency has a wide clinical spectrum with variable age of onset and disease severity. Three apparently unrelated patients with LRBA deficiency, of Georgian Jewish descent, were homozygous for LRBA c.6640C > T, p.R2214*, leading to a stop upstream of the LRBA BEACH domain. Despite carrying the same LRBA genotype, the three patients differed in clinical course: the first patient was asymptomatic until age 25 years; the second presented with failure to thrive at age 3 months; and the third presented at age 7 years with immune cytopenias and severe infections. Two of the patients developed malignancies: the first patient was diagnosed with recurrent Hodgkin's disease at age 36 years, and the second patient developed aggressive gastric cancer at age 15 years. Among Georgian Jews, the carrier frequency of the LRBA p.R2214* allele was 1.6% (4 of 236 Georgian Jewish controls). The allele was absent from other populations. Haplotype analysis showed a shared origin of the mutation. These three patients revealed a pathogenic LRBA founder allele in the Georgian Jewish population, support the diverse and complex clinical spectrum of LRBA deficiency, and support the possibility that LRBA deficiency predisposes to malignancy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CTL4; Georgian Jews; IEI; Immunedysregulation; Inborn errors of immunity; LRBA; PIDD; Primary immunodeficiency disorders

Year:  2022        PMID: 36063261     DOI: 10.1007/s10875-022-01358-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  2 in total

1.  Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA.

Authors:  Louis-Marie Charbonnier; Erin Janssen; Janet Chou; Toshiro K Ohsumi; Sevgi Keles; Joyce T Hsu; Michel J Massaad; Maria Garcia-Lloret; Rima Hanna-Wakim; Ghassan Dbaibo; Abdullah A Alangari; Abdulrahman Alsultan; Daifulah Al-Zahrani; Raif S Geha; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2014-11-17       Impact factor: 10.793

2.  The expansion of human T-bethighCD21low B cells is T cell dependent.

Authors:  Baerbel Keller; Valentina Strohmeier; Ina Harder; Susanne Unger; Kathryn J Payne; Geoffroy Andrieux; Melanie Boerries; Peter Tobias Felixberger; Jonathan J M Landry; Alexandra Nieters; Anne Rensing-Ehl; Ulrich Salzer; Natalie Frede; Susanne Usadel; Roland Elling; Carsten Speckmann; Ina Hainmann; Elizabeth Ralph; Kimberly Gilmour; Marjolein W J Wentink; Mirjam van der Burg; Hye Sun Kuehn; Sergio D Rosenzweig; Uwe Kölsch; Horst von Bernuth; Petra Kaiser-Labusch; Florian Gothe; Sophie Hambleton; Alexandru Daniel Vlagea; Ana Garcia Garcia; Laia Alsina; Gašper Markelj; Tadej Avcin; Julia Vasconcelos; Margarida Guedes; Jing-Ya Ding; Cheng-Lung Ku; Bella Shadur; Danielle T Avery; Nils Venhoff; Jens Thiel; Heiko Becker; Lucía Erazo-Borrás; Claudia Milena Trujillo-Vargas; José Luis Franco; Claire Fieschi; Satoshi Okada; Paul E Gray; Gulbu Uzel; Jean-Laurent Casanova; Manfred Fliegauf; Bodo Grimbacher; Hermann Eibel; Stephan Ehl; Reinhard E Voll; Marta Rizzi; Polina Stepensky; Vladimir Benes; Cindy S Ma; Claudia Bossen; Stuart G Tangye; Klaus Warnatz
Journal:  Sci Immunol       Date:  2021-10-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.